Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LAFAR vs ABEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: LAFAR 0 – 5 ABEO (1 Tie) Matrix Metrics: LAFAR 0 – 10 ABEO

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over LAFAR (LAFAR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LAFAR carries a Unified Composite Score of 47.9/100 (HOLD) at $0.06 (N/M Forward P/E, N/A operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin).

  • Technical & Structure Timing Caution: LAFAR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LAFAR vs ABEO
LAFAR US Equity
LAFAR
Institutional Equity
$0.06
-7.23% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.32β · 187% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.42
-1.22% 1D
Market Cap $167.4M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 60.0 Fund 61.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.9%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $3.39 · SMA50: $4.38

6-Pillar Scorecard Institutional Category Breakdown (LAFAR 0 – 5 ABEO)

Columns: Metric · LAFAR · ABEO
1. Valuation Multiples ABEO
Forward P/E N/M 18.7x
Trailing P/E N/M 18.7x
PEG Ratio N/M N/M
EV / Revenue N/M 3.0x
2. Growth & Scale ABEO
Revenue Growth (YoY) N/A +2745.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $39M
Market Cap N/A $167.4M
3. Profitability & Quality ABEO
Gross Margin N/A -3.5%
Operating Margin N/A -186.1%
Net Profit Margin N/A -160.3%
Return on Equity (ROE) N/A -42.1%
4. Balance Sheet & Cash Flow ABEO
Cash Generation (TTM) N/A -$66M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $50M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABEO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 165.8% (27th %ile)
Put/Call OI Skew N/A 0.26x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LAFAR (0) vs ABEO (10)
Institutional Metric LAFAR ABEO Criterion Row Edge
Market Capitalization
Scale
N/A $167.4M Larger Scale ABEO
Trailing P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Forward P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Revenue Growth (YoY)
Growth
N/A +2745.0% Higher Growth ABEO
Operating Margin (TTM)
Profitability
N/A -186.1% Higher Margin ABEO
Net Profit Margin
Profitability
N/A -160.3% Higher Margin ABEO
Return on Equity (ROE)
Capital Efficiency
N/A -42.1% Higher ROE ABEO
52-Week Range Position
Momentum
0% ($0–$0) 6% ($2–$8) Stronger Trend ABEO
Beta / 30D Volatility
Risk Regime
0.32β · 187% Vol 0.60β · 149% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
47.9 / 100 (HOLD) 49.9 / 100 (HOLD) Higher Composite ABEO
Trailing 12M Revenue (USD)
Operating Scale
N/A $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -3.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$66M ($50M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LAFAR +17.38 pp
LAFAR: -44.27% · ABEO: -61.65%
3M Horizon ABEO +3.65 pp
LAFAR: -56.11% · ABEO: -52.46%
6M Horizon ABEO +6.79 pp
LAFAR: -59.8% · ABEO: -53.01%
1Y Horizon ABEO +6.79 pp
LAFAR: -59.8% · ABEO: -53.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LAFAR vs ABEO. Trailing 12-month operating profitability (LAFAR N/A vs ABEO -186.1%) and valuation multiples (LAFAR N/M vs ABEO 18.7x Forward P/E) are benchmarked directly in Pillar 4 below.

LAFAR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABEO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-3.5%
Op. Margin-186.1%
ROE / Fwd P/E-42.1% · 18.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LAFAR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LAFAR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABEO BREAKDOWN
71d in phase · OBV NEUTRAL
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LAFAR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $167.4M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LAFAR vs ABEO Key Questions & Quantitative Answers

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over LAFAR (LAFAR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LAFAR carries a Unified Composite Score of 47.9/100 (HOLD) at $0.06 (N/M Forward P/E, N/A operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin). Technical & Structure Timing Caution: LAFAR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: LAFAR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). On trailing 12-month operating scale, LAFAR generates N/A in USD-normalized revenue versus $39M for ABEO. In operating R&D and SG&A reinvestment, LAFAR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.

ABEO screens cheaper on headline valuation multiples. LAFAR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LAFAR (N/A ROE) versus ABEO (-42.1% ROE) capital efficiency.

In options market volatility and institutional positioning, LAFAR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 187% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.